So far, 369 of the required 400 patients – 200 with breast cancer and 200 healthy – have been enrolled in the study.
ANGLE is looking to become the first company to receive Food and Drug Administration clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis.
Given the “continued progress” to date, ANGLE remains confident in wrapping up the trial and data analysis in the current quarter.
“The first half of the year has been one of continued progress by ANGLE and we look forward to completing our FDA clinical and analytical studies in metastatic breast cancer in the US in Q1 2019 with only 31 more subjects to recruit,” said chairman Garth Selvey.
Ovarian cancer test progressing well
In the same update, the AIM company confirmed that the pre-study of an ovarian cancer test, which combines Parsortix with its HyCEAD Ziplex analysis platform, is due to start in the current quarter, subject to ethics approval.
“Significant progress has also been achieved in the optimisation of our recently acquired HyCEAD Ziplex platform for downstream analysis in preparation for our ovarian cancer clinical verification study,” added chairman Selvey.
Healthy cash balance
In the six months ended 31 October, revenue and grant income totalled £0.4mln (H1 17/18: £0.2mln).
Loss from continuing operations widened to £4.2mln (H1 17/18: £3.4mln) reflecting planned investment.
Following a £12.7mln fundraise back in June, ANGLE ended the half with £14.9mln in the bank (April 2018: £7.6mln).